Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objectives The aim was to examine the relationship between baseline and on-study apolipoproteins (apo) A-1 and B and lipoprotein(a) [Lp(a)] levels and the development of subsequent cardiovascular (CV) events in the AIM-HIGH Trial. Background Niacin has been reported to lower apoB and Lp(a) and to raise apoA-1. Method Individuals with CV disease and low baseline levels of HDL-C were randomized to simvastatin plus placebo or simvastatin plus extended-release niacin (ERN, 1500–2000 mg/day), with ezetimibe added, as needed, in both groups to maintain an on-treatment LDL-C in the range of 40–80 mg/dL. Hazard ratios (HR) were used to evaluate the relationship between levels of apo A-1, apoB and Lp(a) and CV events in each treatment group. Results Baseline apoB and the apoB/apoA-I ratio were significantly predictive of CV events only for the placebo group (HR=1.17, p=0.018 and HR=1.19, p=0.016). Baseline and on-study Lp(a) were predictive of CV events in both simvastatin+placebo (baseline HR= 1.24, p=0.002 and on-study HR=1.21, p=0.017) and the simvastatin+ERN group (baseline HR=1.25, p=0.001 and on-study HR=1.18 p=0.028). ERN modestly increased 1-year apoA-1 (7%), decreased apoB (13%), decreased the ApoB/ApoA-1 ratio (19%), and decreased Lp(a) 21%, but did not reduce CV events. Conclusions Lp(a) was associated with increased CV risk in both treatment groups indicating that it contributes to residual CV risk. However, there was no evidence that ERN reduced CV risk despite favorable lipoprotein changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Wellcome Trust Case Control Consortium, Trégouët, D.-A., Cardiogenics Consortium, König, I. R., Erdmann, J., Munteanu, A., Braund, P. S., Hall, A. S., Großhennig, A., Linsel-Nitschke, P., et al. (2009) · Nature Genetics · doi:10.1038/ng.314 · Cited by 475
Marcovina, S. M., Albers, J. J., Gabel, B., Koschinsky, M. L., & Gaur, V. P. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.2.246 · Cited by 354
Self-citationEffects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)
Maher, V. M. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530220037029 · Cited by 298
F. T. G. O. C. I., Jaeger, B. R., Richter, Y., Nagel, D., Heigl, F., Vogt, A., Roeseler, E., Parhofer, K., Ramlow, W., Koch, M., et al. (2009) · Nature Reviews Cardiology · doi:10.1038/ncpcardio1456 · Cited by 294
Lamon-Fava, S., Marcovina, S. M., Albers, J. J., Kennedy, H., DeLuca, C., White, C. C., Cupples, L. A., McNamara, J. R., Seman, L. J., Bongard, V., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012526 · Cited by 90
Self-citation
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
A Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137
“6 , 2 0 1 7 Lipoprotein(a) F E B R U A R Y 1 4 , 2 0 1 7 : 6 9 2 – 7 1 1 704 Global Health Outcomes) (45), JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) (44), and LIPID (LongTerm Intervention with Pravastatin in Ischaemic Disease) (58) trials have suggested…”
BackgroundInfluentialReyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationSandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 518
Statin therapy increases lipoprotein(a) levels
Tsimikas, S., Gordts, P. L. S. M., Nora, C., Yeang, C., & Witztum, J. L. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz310 · Cited by 512
Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Self-citationLipoprotein(a) and its Significance in Cardiovascular Disease: A Review
Duarte Lau, F., & Giugliano, R. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0987 · Cited by 363
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Lipoprotein(a) and cardiovascular disease
Nordestgaard, B. G., & Langsted, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01308-4 · Cited by 288
Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
Boffa, M. B., & Koschinsky, M. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0153-2 · Cited by 284
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
O'Donoghue, M. L., Morrow, D. A., Tsimikas, S., Sloan, S., Ren, A. F., Hoffman, E. B., Desai, N. R., Solomon, S. D., Domanski, M., Arai, K., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.042 · Cited by 215
“the highest versus lowest quantile of Lp(a) was employed where available (Supplementary figure 1)(19-26).”
Relationship of Lipoproteins to Cardiovascular Events
Guyton, J. R., Slee, A. E., Anderson, T., Fleg, J. L., Goldberg, R. B., Kashyap, M. L., Marcovina, S. M., Nash, S. D., O'Brien, K. D., Weintraub, W. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.023 · Cited by 182
Self-citationLipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“This includes studies with niacin, which did not a priori enroll patients with elevated Lp(a); in fact Lp(a) levels in these studies were within normal limits.(172,173) The best evidence for potential benefit of Lp(a) lowering has come from studies in which patients received lipid apheresis specifically when they had…”
BackgroundStahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels
Scientific Board of GLAR for the German Apheresis Working Group, Schettler, V. J. J., Neumann, C. L., Peter, C., Zimmermann, T., Julius, U., Hohenstein, B., Roeseler, E., Heigl, F., Grützmacher, P., et al. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00094-4 · Cited by 37
Metadata
- Authors
- Albers, J. J., Slee, A., O'Brien, K. D., Robinson, J. G., Kashyap, M. L., Kwiterovich, P. O., Xu, P., & Marcovina, S. M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 62
- Issue
- 17
- Pages
- 1575-1579
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1959291640
- Cited by
- 318
- References
- 10
- FWCI
- 27.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.